Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2

Robert Kralovics, Soon Siong Teo, Andreas S. Buser, Martin Brutsche, Ralph Tiedt, Andre Tichelli, Francesco Passamonti, Daniela Pietra, Mario Cazzola, Radek C. Skoda

Research output: Contribution to journalArticlepeer-review

Abstract

We identified 13 new gene expression markers that were elevated and one marker, ANKRD15, that was down-regulated in patients with polycythemia vera (PV). These 14 markers, as well as the previously described PRV1 and NF-E2, exhibited the same gene expression alterations also in patients with exogenously activated granulocytes due to sepsis or granulocyte colony-stimulating factor (GCSF) treatment. The recently described V617F mutation in the Janus kinase 2 (JAK2) gene allows defining subclasses of patients with myeloproliferative disorders based on the JAK2 genotype. Patients with PV who were homozygous or heterozygous for JAK2-V617F exhibited higher levels of expression of the 13 new markers, PRV1, and NF-E2 than patients without JAK2-V617F, whereas ANKRD15 was down-regulated in these patients. Our results suggest that the alterations in expression of the markers studied are due to the activation of the Jak/signal transducer and activator of transcription (STAT) pathway through exogenous stimuli (sepsis or G-CSF treatment), or endogenously through the JAK2-V617F mutation.

Original languageEnglish
Pages (from-to)3374-3376
Number of pages3
JournalBlood
Volume106
Issue number10
DOIs
Publication statusPublished - Nov 15 2005

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2'. Together they form a unique fingerprint.

Cite this